logo
Share SHARE
FONT-SIZE Plus   Neg

Regeneron Pharma To Get Addl. Potential Royalty Stream On EU Approval For Ilaris

Regeneron Pharmaceuticals Inc. (REGN: Quote) said it would receive an additional potential royalty stream now that the European Commission or EC has approved Novartis' llaris in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options. Ilaris, a registered trademark of Novartis, is the first biologic approved in the European Union or EU for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection of 150 mg.1

As part of June 2009 agreement with Novartis, Regeneron receives royalties on worldwide sales of Ilaris. The overall royalty rate in the agreement starts at 4% and reaches 15% when annual sales exceed $1.5 billion. In 2012, Regeneron posted annual Ilaris royalties of $2.8 million.

In the EU, Ilaris is specifically indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks in whom non-steroidal anti-inflammatory drugs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The FCC has warned Marriott and other hotel chains to stop the "disturbing trend" of illegally blocking guests' private wi-fi. Marriott, which was fined $600,000 for blocking personal hotspots in hotel rooms and conference spaces, recently stopped the practice after a storm of criticism on social... Apple Inc. said Tuesday after the markets closed that its first quarter profit rose 38% from last year, driven by all time record revenue from iPhone and Mac sales as well as record performance of its App Store. The company's quarterly earnings per share also breezed past Wall Street expectations as did its quarterly sales. We are just a few weeks into 2015 and it has already been a busy year for merger deals and merger talks. Here is a list of some of the M&A stories that have made headlines so far in 2015.
comments powered by Disqus
Follow RTT